SMOFKABIVEN ELECTROLYTE FREE amino acids 5.1% / lipids 3.8% / glucose 12.7% emulsion for intravenous infusion bag 1970 mL Australia - English - Department of Health (Therapeutic Goods Administration)

smofkabiven electrolyte free amino acids 5.1% / lipids 3.8% / glucose 12.7% emulsion for intravenous infusion bag 1970 ml

fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; soya oil, quantity: 60 g/l; olive oil, quantity: 50 g/l; medium chain triglycerides, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: sodium oleate; water for injections; egg lecithin; dl-alpha-tocopherol; sodium hydroxide; glycerol - parenteral nutrition for adult patients when oral or enteral nutrition is impossible, insufficient or contraindicated.

SMOFKABIVEN ELECTROLYTE FREE amino acids 5.1% / lipids 3.8% / glucose 12.7% emulsion for intravenous infusion bag 1477 mL Australia - English - Department of Health (Therapeutic Goods Administration)

smofkabiven electrolyte free amino acids 5.1% / lipids 3.8% / glucose 12.7% emulsion for intravenous infusion bag 1477 ml

fresenius kabi australia pty ltd - soya oil, quantity: 60 g/l; olive oil, quantity: 50 g/l; fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: water for injections; glycerol; dl-alpha-tocopherol; egg lecithin; sodium oleate; sodium hydroxide - parenteral nutrition for adult patients when oral or enteral nutrition is impossible, insufficient or contraindicated.

SMOFKABIVEN amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 2463 mL Australia - English - Department of Health (Therapeutic Goods Administration)

smofkabiven amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 2463 ml

fresenius kabi australia pty ltd - medium chain triglycerides, quantity: 60 g/l; fish oil - rich in omega-3 acids, quantity: 30 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: sodium oleate; dl-alpha-tocopherol; glycerol; egg lecithin; water for injections; sodium hydroxide - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.

SMOFKABIVEN amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 1970 mL Australia - English - Department of Health (Therapeutic Goods Administration)

smofkabiven amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 1970 ml

fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; soya oil, quantity: 60 g/l; olive oil, quantity: 50 g/l; medium chain triglycerides, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; sodium oleate; egg lecithin; glycerol; water for injections; dl-alpha-tocopherol - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.

SMOFKABIVEN amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 1477 mL Australia - English - Department of Health (Therapeutic Goods Administration)

smofkabiven amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 1477 ml

fresenius kabi australia pty ltd - olive oil, quantity: 50 g/l; fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: water for injections; dl-alpha-tocopherol; sodium oleate; sodium hydroxide; egg lecithin; glycerol - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.

SMOFKABIVEN ELECTROLYTE FREE amino acids 5.1% / lipids 3.8% / glucose 12.7% emulsion for intravenous infusion bag 986 mL Australia - English - Department of Health (Therapeutic Goods Administration)

smofkabiven electrolyte free amino acids 5.1% / lipids 3.8% / glucose 12.7% emulsion for intravenous infusion bag 986 ml

fresenius kabi australia pty ltd - medium chain triglycerides, quantity: 60 g/l; fish oil - rich in omega-3 acids, quantity: 30 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: dl-alpha-tocopherol; water for injections; sodium hydroxide; egg lecithin; glycerol; sodium oleate - parenteral nutrition for adult patients when oral or enteral nutrition is impossible, insufficient or contraindicated.

SMOFKABIVEN amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 986 mL Australia - English - Department of Health (Therapeutic Goods Administration)

smofkabiven amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 986 ml

fresenius kabi australia pty ltd - medium chain triglycerides, quantity: 60 g/l; soya oil, quantity: 60 g/l; olive oil, quantity: 50 g/l; fish oil - rich in omega-3 acids, quantity: 30 g/l - injection, intravenous infusion - excipient ingredients: sodium oleate; egg lecithin; sodium hydroxide; glycerol; dl-alpha-tocopherol; water for injections - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.

GLAMIN amino acids/dipeptides 1000mL intravenous  infusion injection bottle Australia - English - Department of Health (Therapeutic Goods Administration)

glamin amino acids/dipeptides 1000ml intravenous infusion injection bottle

fresenius kabi australia pty ltd - alanine, quantity: 16 g/l; glycylglutamine monohydrate, quantity: 30.27 g/l (equivalent: glutamine, qty 20 g); histidine, quantity: 6.8 g/l; methionine, quantity: 5.6 g/l; tryptophan, quantity: 1.9 g/l; threonine, quantity: 5.6 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: glycine, qty 10.27 g; equivalent: lysine, qty 9 g); valine, quantity: 7.3 g/l; arginine, quantity: 11.3 g/l; glycyltyrosine dihydrate, quantity: 3.45 g/l (equivalent: tyrosine, qty 2.28 g; equivalent: glycine, qty 0.94 g); serine, quantity: 4.5 g/l; proline, quantity: 6.8 g/l; glutamic acid, quantity: 5.6 g/l; leucine, quantity: 7.9 g/l; isoleucine, quantity: 5.6 g/l; aspartic acid, quantity: 3.4 g/l; phenylalanine, quantity: 5.85 g/l - injection, intravenous infusion - excipient ingredients: water for injections; citric acid - glamin provides amino acids as part of parenteral nutrition therapy, when oral or enteral nutrition is impossible, insufficient or contraindicated especially in patients with a moderate or severe catabolic status.

GLAMIN amino acids/dipeptides 500mL intravenous   infusion injection bottle Australia - English - Department of Health (Therapeutic Goods Administration)

glamin amino acids/dipeptides 500ml intravenous infusion injection bottle

fresenius kabi australia pty ltd - proline, quantity: 6.8 g/l; isoleucine, quantity: 5.6 g/l; methionine, quantity: 5.6 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: lysine, qty 9 g; equivalent: glycine, qty 10.27 g); serine, quantity: 4.5 g/l; glycylglutamine monohydrate, quantity: 30.27 g/l (equivalent: glycine, qty 10.27 g; equivalent: glutamine, qty 20 g); alanine, quantity: 16 g/l; histidine, quantity: 6.8 g/l; glutamic acid, quantity: 5.6 g/l; tryptophan, quantity: 1.9 g/l; leucine, quantity: 7.9 g/l; valine, quantity: 7.3 g/l; aspartic acid, quantity: 3.4 g/l; phenylalanine, quantity: 5.85 g/l; glycyltyrosine dihydrate, quantity: 3.45 g/l (equivalent: tyrosine, qty 2.28 g; equivalent: glycine, qty 0.94 g); arginine, quantity: 11.3 g/l; threonine, quantity: 5.6 g/l - injection, intravenous infusion - excipient ingredients: citric acid; water for injections - glamin provides amino acids as part of parenteral nutrition therapy, when oral or enteral nutrition is impossible, insufficient or contraindicated especially in patients with a moderate or severe catabolic status.